Overview

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Status:
Recruiting

Trial end date:
2023-11-08

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation

Collaborators:

European Network for Gynaecological Oncological Trial groups(ENGOT)
GOG Foundation
Gynecologic Oncology Group